|1.||Boers, Maarten: 9 articles (06/2015 - 02/2002)|
|2.||Braun, J: 9 articles (12/2013 - 01/2002)|
|3.||Sieper, J: 9 articles (04/2011 - 01/2002)|
|4.||van der Heijde, Désirée: 7 articles (01/2014 - 01/2003)|
|5.||O'Dell, James R: 7 articles (08/2013 - 05/2002)|
|6.||Sontheimer, Harald: 7 articles (08/2012 - 08/2005)|
|7.||Gout, Peter W: 7 articles (03/2010 - 01/2003)|
|8.||Smolen, J S: 7 articles (07/2009 - 06/2000)|
|9.||Lems, Willem F: 6 articles (06/2015 - 07/2004)|
|10.||Dhaneshwar, Suneela S: 6 articles (04/2014 - 04/2007)|
12/01/1985 - "Sulfasalazine is of proven efficacy as maintenance therapy in ulcerative colitis. "
09/01/1990 - "Since the development of sulfasalazine about a half century ago, the prognosis for patients with ulcerative colitis has improved significantly. "
04/01/1985 - "In the case of sulphasalazine, adult slow acetylators require a lower daily dose of the drug than fast acetylators in order to maintain ulcerative colitis in remission without significant side effects. "
08/01/1985 - "The disparity of the therapeutic efficacy and effects on NK activity of sulphasalazine and its derivatives in vitro may suggest that NK activity is not a major pathogenic mechanism in ulcerative colitis. "
05/01/1983 - "Sulfasalazine is of major benefit in preventing relapses in patients with ulcerative colitis in remission. "
03/01/1985 - "However, its safety profile is far superior, and very long-term treatment with sulphasalazine is a safe option for treatment of rheumatoid arthritis."
09/01/2014 - "Sulfasalazine (SSZ) and tofacitinib are effective for treating rheumatoid arthritis, however, their effects on chondrocytes have not been fully understood. "
08/01/1993 - "We conclude that sulphasalazine is equally effective in rheumatoid arthritis in the elderly as in the young. "
01/01/1993 - "Sulfasalazine is an efficient treatment for rheumatoid arthritis (RA), but its mode of action is not known. "
01/01/1992 - "The influence of acetylator status on the therapeutic efficacy and the toxicity of sulphasalazine (SASP) was assessed in 106 patients with rheumatoid arthritis (RA). "
|3.||Crohn Disease (Crohn's Disease)
04/01/1986 - "Crohn's disease was associated with a significant reduction in family size independent of steroid or sulphasalazine treatment."
02/01/1985 - "It is also suggested that Salazopyrin is more effective in cases with short duration of symptoms, i.e., in cases previously untreated for Crohn's disease. "
05/01/1991 - "Sulfasalazine has not been uniformly effective in preventing relapse in Crohn's disease, although many clinicians continue its use in patients who respond initially. "
12/01/1983 - "In treatment of Crohn's disease, sulfasalazine has been shown to be effective when disease involves the colon or the colon and small intestine. "
01/01/2010 - "In conclusion, sulfasalazine shows modest efficacy for the treatment of active Crohn's disease. "
01/01/2010 - "Sulfasalazine was more likely to induce remission (RR 1.38; 95% CI 1.02 to 1.87; n = 263) compared to placebo with benefit confined mainly to patients with colitis. "
11/01/1987 - "In haemorrhagic recto-colitis, these various preparations have, in the whole, a similar effectiveness to that of Salazopyrin in controlling moderately active forms or in keeping the patient in remission. "
08/01/1984 - "A second trial with sulfasalazine was, again, followed by a rapid and sever relapse of the colitis. "
11/06/2015 - "Amelioration of colitis by either of the drug candidates was comparable to that achieved by orally administered sulfasalazine or 5-ASA. "
06/01/2015 - "Rats from the non-colitis and non-treated colitis groups were administered vehicle (saline, 5 ml/kg) orally and another group received sulfasalazine (50mg/kg/day). "
|5.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
08/01/1992 - "Sulfasalazine is an important therapeutic agent in the management of chronic inflammatory bowel disease (CIBD). "
08/01/2001 - "5-ASA, sulfasalazine and 6-MP, while beneficial in inflammatory bowel disease, do not directly control MAdCAM-1, and are beneficial through inhibition of other inflammatory processes."
10/01/1991 - "Sulphasalazine and 5-ASA, at concentrations of 10(-5)-10(-3) M significantly inhibit lipid peroxidation, suggesting an antioxidant action that may explain the efficacy of these drugs in treating inflammatory bowel disease. "
12/01/1981 - "On the contrary, sulphasalazine resulted in a reduced response which was significantly greater for the group with inflammatory bowel disease than the control group (P less than 0.05). "
01/01/2001 - "Since its synthesis in the 1930s and subsequent introduction, sulfasalazine has been an effective treatment for inflammatory bowel disease. "
|3.||Adrenal Cortex Hormones (Corticosteroids)
|2.||Drug Therapy (Chemotherapy)